Fortrea Holdings Inc. (FTRE) SEC Filings & Earnings Calls
EquiReason read 14 Fortrea Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-30 — Appointment of Carrie Russell as Chief Accounting Officer, effective October 5, 2026; compensation details provided..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
30 Sep 20268-K · 5.02Appointment of Carrie Russell as Chief Accounting Officer, effective October 5, 2026; compensation details provided.open
Risks flagged
No material risk; routine executive appointment.
“No disagreements or material interests disclosed.”
10 Sep 20268-K · 5.02Fortrea reinstated Jason Knoblauch as CFO after a temporary restraining order was lifted. David Smith stepped down as Interim CFO but remains on the board. The prior legal dispute with Knoblauch's former employer was settled.open
Risks flagged
Legal dispute with former employer resolved but indicates potential non-compete/restrictive covenant risks
“lawsuit filed by Mr. Knoblauch’s prior employer against him and the Company alleging that Mr. Knoblauch violated certain restrictive covenants and retained confidential information” · word for word
29 Jul 202610-QQuarterly revenue declined 4.5% YoY; direct cost ratio improved 170 bps; operating cash flow turned positive.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $678M | -5% y/y |
| Backlog · 2026-06-30 | $7.80B | |
| Cash and Cash Equivalents · 2026-06-30 | $169M | |
| Operating Cash Flow · H1-2026 | $12M | |
| Capital Expenditures · H1-2026 | $17M |
Risks flagged
Revenue Decline and FSP Demand Weakness
“The 4.9% decrease in organic revenues was due to lower pass through costs as well as lower demand for our functional service provider business.” · word for word
Customer Cancellation Risk
“The majority of our contracts contain early termination provisions that typically require notice periods ranging from 30 to 90 days.” · word for word
29 Jul 20268-K · 2.02, 5.02Revenue $678M (-4% y/y); Book-to-bill ratio 1.06; Backlog $7.80B; Guidance: Revenue $2,620M-$2,690M; Adjusted EBITDA $205M-$220Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $678M | -5% y/y |
| Book-to-bill ratio · Q2-2026 | $1.06 | |
| Backlog · Q2-2026 | $7.80B | |
| Adjusted EBITDA · Q2-2026 | $59M | +7% y/y |
| Adjusted net income · Q2-2026 | $23M | +29% y/y |
| Adjusted diluted EPS · Q2-2026 | $0.23 | +21% y/y |
| GAAP net loss · Q2-2026 | $-13M | |
| Operating cash flow · Q2-2026 | $29M | |
| Free cash flow · Q2-2026 | $20M |
Guidance
Revenue $2,620M-$2,690M; Adjusted EBITDA $205M-$220M
Increased full-year 2026 guidance reflecting confidence in business momentum and execution.
Risks flagged
Revenue declined 4.5% YOY, though adjusted profitability improved.
“Revenue $678.2M vs $710.3M prior year, down 4.5%”
GAAP net loss persists, though significantly improved from prior year.
“GAAP net loss $(13.2)M vs $(374.9)M prior year (includes goodwill impairment)”
14 Jul 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Key finance leadership departures may disrupt financial reporting and controls.
“CAO and CFO both transitioning; interim appointments.”
5 May 202610-QRevenues $636M (-2% y/y); Direct costs as a % of revenues 80.6; Selling, general and administrative expenses $100M (-18% y/y)open
Figures in the filing · each found in the filing text
| Revenues · Q1-2026 | $637M | -2% y/y |
| Direct costs as a % of revenues · Q1-2026 | 80.6% | |
| Selling, general and administrative expenses · Q1-2026 | $101M | -18% y/y |
| Backlog · 2026-03-31 | $7.80B | |
| Cash and cash equivalents · 2026-03-31 | $148M | +45% y/y |
| Net cash used for operating activities · Q1-2026 | $-17M | +86% y/y |
| Capital expenditures · Q1-2026 | $8M | +176% y/y |
Risks flagged
Revenue decline from FSP demand weakness
“The 3.2% decrease in organic revenues was due to lower pass through costs as well as lower demand for our functional service provider business.” · word for word
Backlog cancellation risk
“Our backlog also reflects any cancellation or adjustment activity related to these awards.” · word for word
5 May 20268-K · 2.02Revenues $636M (-2% y/y); Book-to-bill ratio 1.15; Adjusted EBITDA $47M (+55% y/y); Guidance: Revenue $2,550M-$2,650M, adj EBITDA $190M-$220Mearningsopen
Figures in the filing · each found in the filing text
| Revenues · Q1-2026 | $637M | -2% y/y |
| Book-to-bill ratio · Q1-2026 | $1.15 | |
| Adjusted EBITDA · Q1-2026 | $47M | +55% y/y |
| Adjusted net income · Q1-2026 | $15M | +700% y/y |
| Adjusted diluted EPS · Q1-2026 | $0.16 | +700% y/y |
| Backlog · Q1-2026 | $7.85B |
Guidance
Revenue $2,550M-$2,650M, adj EBITDA $190M-$220M
Full year guidance affirmed. Strong Q1 performance with improving book-to-bill and margins.
Risks flagged
Revenue slightly declined year-over-year.
“Revenue $636.5M vs $651.3M in Q1 2025.”
27 Apr 2026DEF 14AAnnual proxy statement filed, disclosing executive compensation, governance, and 2025 financial performance including CEO transition and goodwill impairment.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $2.72B | |
| Adjusted EBITDA · FY2025 | $190M | -6% y/y |
| Backlog · 2025-12-31 | $7.73B | +0% y/y |
| Book-to-bill ratio · FY2025 | $1.02 | |
| Net loss from continuing operations · FY2025 | $-986M | |
| Goodwill and other asset impairment · FY2025 | $798M | |
| Debt paydown · FY2025 | $76M | |
| Net savings · FY2025 | $93M | |
| Employees · 2025-12-31 | 14,300 | |
| Shares outstanding · 2026-04-15 | 94,584,730 |
Risks flagged
Goodwill impairment risk
“Goodwill and other asset impairment 797.9” · word for word
CEO transition risk
“In May 2025, Mr. Pike stepped down as the Company's Chief Executive Officer...the Board appointed Mr. Neupert...to succeed Mr. Pike as Interim CEO...Mr. Thakral assumed the Chief Executive role in August 2025.” · word for word
Restructuring risk
“Restructuring and other charges 49.1”
Spin-related costs risk
“One-time spin-related costs 24.7”
26 Feb 20268-K · 2.02Revenue $2.72B (+1% y/y); Adjusted EBITDA $190M (-6% y/y); Backlog $7.73B; Guidance: FY2026 revenue $2,550M-$2,650M vs FY2025 $2,723.4M; adjusted EBITDA $190M-$220M vs $189.9Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $2.72B | +1% y/y |
| Adjusted EBITDA · FY2025 | $190M | -6% y/y |
| Backlog · Q4-2025 | $7.73B | |
| Book-to-bill ratio · Q4-2025 | $1.14 | |
| GAAP net loss · FY2025 | $-986M | |
| Cash and cash equivalents · Q4-2025 | $175M | |
| Operating cash flow · FY2025 | $114M | |
| Free cash flow · FY2025 | $88M |
Guidance
FY2026 revenue $2,550M-$2,650M vs FY2025 $2,723.4M; adjusted EBITDA $190M-$220M vs $189.9M
Revenue guidance cut indicates expected decline, but backlog and book-to-bill show some demand stability. Margin guidance roughly flat.
Risks flagged
Revenue decline guidance indicates demand weakness in CRO market.
“FY2026 revenue guidance midpoint $2,600M vs FY2025 actual $2,723.4M.”
Goodwill impairment of $797.9M in H1 2025 signals past overvaluation and market cap decline.
“non-cash goodwill impairment charge of $797.9 million recognized in the first half of 2025” · word for word
26 Feb 202610-KRevenue $2.72B (+1% y/y); Direct costs as % of revenue 81.5; Goodwill impairment $798Mopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $2.72B | +1% y/y |
| Direct costs as % of revenue · FY2025 | 81.5% | |
| Goodwill impairment · Clinical Development · FY2025 | $798M | |
| Cash and cash equivalents · 2025-12-31 | $175M | +47% y/y |
| Operating cash flow · FY2025 | $114M | -57% y/y |
| Capital expenditures · FY2025 | $25M | -1% y/y |
Risks flagged
Goodwill impairment risk
“Goodwill impairment for 2025 was $797.9. The impairment was specific to the Clinical Development reporting unit.” · word for word
Revenue concentration on clinical development
“lower clinical development revenues resulting primarily from the mix of complex and longer duration studies in our portfolio as well as lower functional service provider revenue” · word for word
Margin pressure from pass-through costs
“Direct costs increased 2.7% in 2025, as compared with 2024, and increased as a percentage of revenues to 81.5% in 2025, as compared to 80.2% in 2024.” · word for word
20 Nov 20258-K · 7.01Fortrea Holdings Inc. announces expiration of debt tender offer to purchase up to $75.744M of its 7.500% Senior Secured Notes due 2030; accepted $75.743M aggregate principal amount at a proration factor of 0.154199.open
Figures in the filing · each found in the filing text
| aggregate principal amount of notes tendered · 2025-11-18 | $76M |
Risks flagged
Debt tender offer reduces leverage but may signal liquidity management or refinancing needs.
“tender offer to purchase for cash up to $75,744,000 of outstanding 7.500% Senior Secured Notes due 2030”
5 Nov 202510-QFortrea reported Q3 2025 revenue of $701.3M, up 3.9% YoY, but gross margin contracted significantly due to higher pass-through costs.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $701M | +4% y/y |
| Operating cash flow · 9M-2025 | $-16M | |
| Cash and cash equivalents · Q3-2025 | $131M | |
| Backlog · Q3-2025 | $7.60B |
Risks flagged
Goodwill impairment risk
“During the first and second quarters of 2025, due to sustained declines in our share price and uncertainties in global macroeconomic conditions, we determined that indicators of impairment existed.” · word for word
Margin pressure from pass-through costs
“Direct costs increased as a percentage of revenues to 82.5% during the three months ended September 30, 2025 as compared to 78.0% in the corresponding period in 2024.” · word for word
5 Nov 20258-K · 2.02Revenue $701M (+4% y/y); GAAP net loss $-16M; Adjusted EBITDA $51M (-21% y/y); Guidance: Revenue raised to $2.7B-$2.75B; adjusted EBITDA narrowed to $175M-$195Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $701M | +4% y/y |
| GAAP net loss · Q3-2025 | $-16M | |
| Adjusted EBITDA · Q3-2025 | $51M | -21% y/y |
| GAAP diluted loss per share · Q3-2025 | $-0.17 | |
| Adjusted diluted earnings per share · Q3-2025 | $0.12 | |
| Backlog · Q3-2025 | $7.64B | |
| Book-to-bill ratio · Q3-2025 | $1.13 | |
| Year-to-Date Revenue · 9M-2025 | $2.06B | +3% y/y |
| Year-to-Date Adjusted EBITDA · 9M-2025 | $136M | -7% y/y |
Guidance
Revenue raised to $2.7B-$2.75B; adjusted EBITDA narrowed to $175M-$195M
Revenue guidance raised on strong backlog; EBITDA guidance narrowed but lower than prior expectations; margin pressure from cost structure.
Risks flagged
Goodwill impairment of $797.9M due to share price decline and discount rate increase, indicating potential further asset write-downs.
“Year-to-Date GAAP net loss was $(953.7) million, inclusive of a non-cash goodwill impairment charge of $797.9 million.” · word for word
Adjusted EBITDA declining despite revenue growth suggests margin pressure from cost structure or pricing.
“Third quarter adjusted EBITDA was $50.7 million, compared to third quarter of 2024 adjusted EBITDA of $64.2 million.” · word for word
Macroeconomic and market-driven discount rate increase impacting valuation; customer concentration and international operations risks.
“The goodwill impairments primarily resulted from declines in the Company’s share price, as well as a macroeconomic market-driven increase to the discount rate.”
Fortrea Holdings Inc. — questions
- What did Fortrea Holdings Inc. file recently?
- 14 SEC filings in the last 12 months. Latest: 8-K on 2026-09-30 — Appointment of Carrie Russell as Chief Accounting Officer, effective October 5, 2026; compensation details provided.
Every figure on this page comes from Fortrea Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.